We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ActivX Announces Expansion of Collaboration Agreement With Pfizer
News

ActivX Announces Expansion of Collaboration Agreement With Pfizer

ActivX Announces Expansion of Collaboration Agreement With Pfizer
News

ActivX Announces Expansion of Collaboration Agreement With Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ActivX Announces Expansion of Collaboration Agreement With Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ActivX Biosciences, Inc., a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., has announced that it has renewed its strategic collaborative agreement with Pfizer that encompasses discovery to developmental stage projects across multiple research sites of Pfizer's Global Research and Development organization.

ActivX has previously announced an expansion of its collaboration with Pfizer in February 2005.

Under the terms of the agreement, ActivX will apply its chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, proteomic profiling, compound selectivity and biological activity, and mechanisms of toxicity.

"The Pfizer collaboration is an important component of our scientific and business strategy," stated Dr. John W. Kozarich, Chairman and President at ActivX.

"Its renewal for a third year is a testimony to the value that the ActivX technology has added to Pfizer R&D programs," he added.

Financial terms of this transaction include an upfront technology access fee along with research support payments by Pfizer.

Advertisement